EP Patent

EP3235496A1 — Treatment of acute renal failure

Assigned to Noorik Biopharmaceuticals AG · Expires 2017-10-25 · 9y expired

What this patent protects

Methods and formulations comprising an endothelin receptor antagonist such as ambrisentan are provided for the treatment and prevention of acute renal failure associated with renal vasoconstriction.

USPTO Abstract

Methods and formulations comprising an endothelin receptor antagonist such as ambrisentan are provided for the treatment and prevention of acute renal failure associated with renal vasoconstriction.

Drugs covered by this patent

Patent Metadata

Patent number
EP3235496A1
Jurisdiction
EP
Classification
—
Expires
2017-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Noorik Biopharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.